OINDPnews


H&T Presspart Low GWP Banner

Business

CBC Corporation partners with Iconovo on generic Symbicort

Iconovo has announced that development of a generic budesonide/formoterol DPI based on its IcoRes inhaler has been transferred to CBC Corporation. Amneal signed a development and licensing deal for the generic version of Symbicort in 2016; CBC will now assume all of Amneal's obligations under that deal. The original agreement with Amneal was described as having … [Read more...] about CBC Corporation partners with Iconovo on generic Symbicort

Altimmune announces new funding, positive results for NasoVax flu vaccine

Altimmune announced that it has raised $14 million in a registered direct offering, with net proceeds of about $12.7 million. The company also said that an extension of a Phase 2 study of its NasoVax intranasal flu vaccine found that subjects were still protected against the flu more than a year after vaccination. The company said that 8 subjects from the original … [Read more...] about Altimmune announces new funding, positive results for NasoVax flu vaccine

Endo files suit against Perrigo alleging infringement of Nascobal patents

Perrigo has announced that Endo Pharmaceuticals filed a patent suit on March 1, 2019 in the United States District Court for the District of Delaware in response to a Perrigo ANDA for a generic version of Nascobal cyanocobalamin nasal spray. Nascobal was originally approved by the FDA in 2015. The Orange Book lists 6 patents for Nascobal nasal spray, all with … [Read more...] about Endo files suit against Perrigo alleging infringement of Nascobal patents

Oyster Point raises $93 million for Phase 3 development of intranasal dry eye therapies

Oyster Point Pharma said that it has raised $93 million in a Series B financing round and will use the proceeds for continued development of its OC-01 and OC-02 nicotine acetylcholine receptor (nAChR) agonist nasal sprays for the treatment of dry eye disease. In October 2018, Oyster Point announced that Phase 2b studies of each of the two nasal sprays had met … [Read more...] about Oyster Point raises $93 million for Phase 3 development of intranasal dry eye therapies

Merxin and Perlen Packaging team up to develop cannabis inhalers

Merxin Ltd and Perlen Packaging have announced that they will co-develop inhaled cannabis products based on Perlen’s BLISTair single use dry powder inhaler, with Merxin developing the formulations and marketing the cannabis DPIs. The BLISTair device is completely manufactured on a blister machine, without any molded parts, creating an inhaler from thermoformed … [Read more...] about Merxin and Perlen Packaging team up to develop cannabis inhalers

Opiant stops development of OPNT001 naloxone nasal spray for the treatment of bulimia

Opiant Pharmaceuticals said that it has discontinued development of OPNT001 naloxone nasal spray for the treatment of bulimia nervosa (BN) after a Phase 2 study failed to meet its primary endpoint. The company had announced the initiation of the study in March 2017. Opiant CEO Roger Crystal commented, “Based on these results, Opiant will not allocate further … [Read more...] about Opiant stops development of OPNT001 naloxone nasal spray for the treatment of bulimia

OtiTopic gets patents for inhaled aspirin for the treatment of myocardial infarction

The US Patent and Trademark Office (USPTO) has granted OtiTopic, Inc. two patents covering its Asprihale (OTI-0726) inhaled aspirin formulation, which OtiTopic is developing as a rescue treatment for suspected myocardial infarction (MI), the company announced. According to OtiTopic, the Asprihale DPI is also covered by utility patents from the US, Japan, and … [Read more...] about OtiTopic gets patents for inhaled aspirin for the treatment of myocardial infarction